{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:48Z","timestamp":1793948448841,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031531","name":"Travere Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001463","name":"American Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001463","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1053\/j.ajkd.2024.08.011","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T12:36:16Z","timestamp":1729686976000},"page":"610-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis"],"prefix":"10.1053","volume":"85","author":[{"given":"Laura H.","family":"Mariani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Trachtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Denburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulysses","family":"Diva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Greasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Hladunewich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jula K.","family":"Inrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radko","family":"Komers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Philippe","family":"Laurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"Nachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisha L.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1053\/j.ajkd.2024.08.011_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28701","article-title":"Comparing kidney health outcomes in children, adolescents, and adults with focal segmental glomerulosclerosis","volume":"5","author":"Gipson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.011_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4S","key":"10.1053\/j.ajkd.2024.08.011_bib3","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"11S","key":"10.1053\/j.ajkd.2024.08.011_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1681\/ASN.20233411S1270a","article-title":"Incidence rates of primary focal segmental glomerulosclerosis (FSGS) within a diverse adult Southern California population, 2010-2021","volume":"34","author":"Munis","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4 suppl 1","key":"10.1053\/j.ajkd.2024.08.011_bib5","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2022.02.001","article-title":"US Renal Data System 2021 annual data report: epidemiology of kidney disease in the United States","volume":"79","author":"Johansen","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.011_bib6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1517\/14656566.6.9.1539","article-title":"Treatment of focal segmental glomerulosclerosis","volume":"6","author":"Meyrier","year":"2005","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.011_bib7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2215\/CJN.05900420","article-title":"Infection-related acute care events among patients with glomerular disease","volume":"15","author":"Glenn","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2024.08.011_bib8","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ekir.2019.08.019","article-title":"Steroid-associated side effects in patients with primary proteinuric kidney disease","volume":"4","author":"Oh","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1053\/j.ajkd.2024.08.011_bib9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2215\/CJN.01140113","article-title":"Fostering innovation, advancing patient safety: the kidney health initiative","volume":"8","author":"Archdeacon","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2024.08.011_bib12","series-title":"BEST (Biomarkers, EndpointS, and Other Tools)","article-title":"FDA-NIH Biomarker Working Group. Validated surrogate endpoint","year":"2020"},{"key":"10.1053\/j.ajkd.2024.08.011_bib13","series-title":"Guidance for Industry: Expedited Programs for Serious Conditions\u2014Drugs and Biologics","year":"2014"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.011_bib14","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.kint.2016.06.020","article-title":"The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases","volume":"90","author":"Hogan","year":"2016","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.011_bib15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/aje\/kwn209","article-title":"Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality","volume":"168","author":"Heerspink","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.011_bib16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.011_bib17","first-page":"97","article-title":"Laboratory measurement of urine albumin and urine total protein in screening for proteinuria in chronic kidney disease","volume":"32","author":"Martin","year":"2011","journal-title":"Clin Biochem Rev"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.011_bib18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1515\/cclm-2012-0768","article-title":"A\u00a0reference system for urinary albumin: current status","volume":"51","author":"Lieske","year":"2013","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.011_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s004670100639","article-title":"Primary focal segmental glomerulosclerosis in children: prognostic factors","volume":"16","author":"Martinelli","year":"2001","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.011_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2215\/CJN.02560315","article-title":"Complete remission in the Nephrotic Syndrome Study Network","volume":"11","author":"Gipson","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.011_bib21","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1681\/ASN.2016101121","article-title":"Long-term outcome of steroid-resistant nephrotic syndrome in children","volume":"28","author":"Trautmann","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2024.08.011_bib22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.011_bib23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1053\/j.ajkd.2019.12.019","article-title":"Approach to diagnosis and management of primary glomerular diseases due to podocytopathies in adults: core curriculum 2020","volume":"75","author":"Ahn","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.011_bib24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.011_bib25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.ackd.2014.05.009","article-title":"The pathogenesis of focal segmental glomerulosclerosis","volume":"21","author":"Jefferson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.011_bib26","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.011_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease","volume":"31","author":"Siragy","year":"2010","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2024.08.011_bib28","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1681\/ASN.2013020173","article-title":"Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases","volume":"24","author":"Wickman","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.011_bib29","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s00467-023-05876-3","article-title":"The association of low birthweight and prematurity on outcomes in children and adults with nephrotic syndrome\u2014a NEPTUNE cohort study","volume":"38","author":"Hingorani","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.011_bib30","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1681\/ASN.2005010055","article-title":"Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene","volume":"16","author":"Wharram","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.011_bib31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1681\/ASN.2021060751","article-title":"Serum protein exposure activates a core regulatory program driving human proximal tubule injury","volume":"33","author":"Lidberg","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.011_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrneph.2010.174","article-title":"Tubular toxicity of proteinuria","volume":"7","author":"Baines","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2024.08.011_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ndt\/14.suppl_3.68","article-title":"Clinical picture and outcome of primary focal segmental glomerulosclerosis","volume":"14","author":"Korbet","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.011_bib34","first-page":"115","article-title":"Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes","volume":"33","author":"Wehrmann","year":"1990","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.011_bib35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00467-005-2097-0","article-title":"Differential risk of remission and ESRD in childhood FSGS","volume":"21","author":"Gipson","year":"2006","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.011_bib36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0272-6386(95)90120-5","article-title":"Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment","volume":"25","author":"Rydel","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2024.08.011_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/j.ajkd.2020.04.014","article-title":"Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis","volume":"77","author":"Troost","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.011_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.34067\/KID.0006172020","article-title":"Focal segmental glomerulosclerosis, risk factors for end stage kidney disease, and response to immunosuppression","volume":"2","author":"Forster","year":"2020","journal-title":"Kidney360"},{"issue":"4","key":"10.1053\/j.ajkd.2024.08.011_bib39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.011_bib40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0272-6386(12)80128-4","article-title":"Primary focal segmental glomerulosclerosis: clinical course and response to therapy","volume":"23","author":"Korbet","year":"1994","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.011_bib41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0272-6386(95)90566-9","article-title":"Primary focal segmental glomerular sclerosis in adults: prognostic value of histologic variants","volume":"25","author":"Schwartz","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2024.08.011_bib42","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/0002-9343(87)90155-0","article-title":"Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study","volume":"82","author":"Pei","year":"1987","journal-title":"Am J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2024.08.011_bib43","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.ekir.2023.07.022","article-title":"Implications of complete proteinuria remission at any time in focal segmental glomerulosclerosis: sparsentan DUET Trial","volume":"8","author":"Trachtman","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.011_bib44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/qjmed\/hci072","article-title":"Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units","volume":"98","author":"Stirling","year":"2005","journal-title":"QJM"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.011_bib45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2215\/CJN.04780517","article-title":"An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis","volume":"13","author":"Troost","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.08.011_bib46","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A\u00a0randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2024.08.011_bib47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.V7156","article-title":"A\u00a0randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children","volume":"7","author":"Lieberman","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"26","key":"10.1053\/j.ajkd.2024.08.011_bib49","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus Irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.08.011_bib50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624010382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624010382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:25:00Z","timestamp":1762280700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638624010382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0272638624010382"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.08.011","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}